Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV

References

• Riebensahm C, Berzigotti A, Surial B, et al. Factors associated with liver steatosis in people with human immunodeficiency virus on contemporary antiretroviral therapy. Open Forum Infect Dis. 2022;9(11):ofac538.
   PubMed Web of Science ®Google Scholar
• Bailin SS, Gabriel CL, Wanjalla CN, et al. Obesity and weight gain in persons with HIV. Curr HIV/AIDS Rep. 2020;17(2):138–150.
   PubMed Web of Science ®Google Scholar
• Kuo PH, Sun HY, Chuang YC, et al. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. Int J Infect Dis. 2020;92:71–77.
   PubMed Web of Science ®Google Scholar
• Rebeiro PF, Jenkins CA, Bian A, et al. Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada. Clin Infect Dis. 2021;73(7):e2234–e2242.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Carter CC, Melbourne K, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73(8):1440–1451.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–1389.
   PubMed Web of Science ®Google Scholar
• Bai R, Lv S, Wu H, et al. Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis. BMC Infect Dis. 2022;22(1):118.
   PubMed Web of Science ®Google Scholar
• Sjaarda A, Bernstein A, Sparks A, et al. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy. Infection. 2022;50(2):407–412.
   PubMed Web of Science ®Google Scholar
• Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471–e477.
   PubMed Web of Science ®Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267–1274.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815.
   PubMed Web of Science ®Google Scholar
• Surial B, Mugglin C, Calmy A, et al. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study. Ann Intern Med. 2021;174(6):758–767.
   PubMed Web of Science ®Google Scholar
• Chandiwana NC, Siedner MJ, Marconi VC, et al. Weight gain after HIV therapy initiation: pathophysiology and implications. J Clin Endocrinol Metab. 2023;109(2):e478–e487.
   Web of Science ®Google Scholar
• Garcia M, Martellosio JP, Giraud V, et al. Efficacy and safety of Doravirine-Based regimens in real life: a prospective monocentric French study. AIDS Res Hum Retroviruses. 2022;38(10):779–781.
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Antoni MD, Castelli F, et al. Real-life use of doravirine in treatment-experienced people living with HIV: a multicenter Italian study. Medicine. 2022;101(30):e29855.
   PubMed Web of Science ®Google Scholar
• Johnson M, Kumar P, Molina J-M, et al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: Results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019;81(4):463–472.
   PubMed Web of Science ®Google Scholar
• Orkin C, Elion R, Thompson M, et al. Changes in weight and BMI with first-line doravirine-based therapy. AIDS. 2021;35(1):91–99.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Hao T, Rimm EB, et al. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011;364(25):2392–2404.
   PubMed Web of Science ®Google Scholar
• Douketis JD, Macie C, Thabane L, et al. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond). 2005;29(10):1153–1167.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102–S138.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Mohaweche R, Morrow M, et al. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV. J Antimicrob Chemother. 2023;79(1):179–185.
   Web of Science ®Google Scholar
• Yuh B, Tate J, Butt AA, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1852–1859.
   PubMed Web of Science ®Google Scholar
• Chang E, Sekhar R, Patel S, et al. Dysregulated energy expenditure in HIV-infected patients: a mechanistic review. Clin Infect Dis. 2007;44(11):1509–1517.
   PubMed Web of Science ®Google Scholar
• Mangili A, Murman DH, Zampini AM, et al. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 2006;42(6):836–842.
   PubMed Web of Science ®Google Scholar
• Martínez-Sanz J, Serrano-Villar S, Muriel A, et al. Metabolic-Related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study. Clin Infect Dis. 2023;76(3):e652–e660.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666–e676.
   PubMed Web of Science ®Google Scholar
• Mallon PW, Brunet L, Hsu RK, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021;24(4):e25702.
   PubMed Web of Science ®Google Scholar
• Plum P-E, Maes N, Sauvage A-S, et al. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect Dis. 2021;21(1):910.
   PubMed Web of Science ®Google Scholar
• Cahn P, Sierra Madero J, Arribas JR, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection. AIDS. 2022;36(1):39–48.
   PubMed Web of Science ®Google Scholar
• Bhutani S, vanDellen MR, Cooper JA. Longitudinal weight gain and related risk behaviors during the COVID-19 pandemic in adults in the US. Nutrients. 2021;13(2):671.
   PubMed Web of Science ®Google Scholar
• Goitia J, Chen A, Patel S, et al. Factors associated with weight gain during the COVID-19 pandemic. Obes Res Clin Pract. 2022;16(2):174–176.
   PubMed Web of Science ®Google Scholar
• Mulugeta W, Desalegn H, Solomon S. Impact of the COVID-19 pandemic lockdown on weight status and factors associated with weight gain among adults in Massachusetts. Clin Obes. 2021;11(4):e12453.
   PubMed Web of Science ®Google Scholar
• Almandoz JP, Xie L, Schellinger JN, et al. Changes in body weight, health behaviors, and mental health in adults with obesity during the COVID-19 pandemic. Obesity. 2022;30(9):1875–1886.
   PubMed Web of Science ®Google Scholar
• Sauceda JA, Dubé K, Harris O, et al. Brief report: the influence of the COVID-19 pandemic on the physical, social, and mental health of black and latinx young people with HIV in the United States. J Acquir Immune Defic Syndr. 2023;93(3):187–190.
   PubMed Web of Science ®Google Scholar
• Fujioka K, Harris SR. Barriers and solutions for prescribing obesity pharmacotherapy. Endocrinol Metab Clin North Am. 2020;49(2):303–314.
   PubMed Web of Science ®Google Scholar
• Hung A, Wong ES, Dennis PA, et al. Real world use of anti-obesity medications and weight change in veterans. J Gen Intern Med. 2023;39(4):519–528.
   PubMed Web of Science ®Google Scholar
• Granara B, Laurent J. Provider attitudes and practice patterns of obesity management with pharmacotherapy. J Am Assoc Nurse Pract. 2017;29(9):543–550.
   PubMed Web of Science ®Google Scholar